Physician profile
Cheryle Hart
NPI 1003076928
$967.56
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $580 · 2020: $388.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $325.87 | 2019-2020 | |
| Mdd US Operations, LLC | $231.29 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $208.87 | 2019-2020 | |
| Pfizer INC. | $40.80 | 2019 | |
| Shionogi INC | $30.20 | 2019 | |
| Indivior INC. | $29.04 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.67 | 2019 | |
| Pacira Therapeutics, INC. | $21.20 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.87 | 2019 | |
| Horizon Therapeutics Plc | $14.07 | 2020 | |
| Alfasigma USA, INC. | $12.61 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $12.07 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryle Hart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.